DIEBOLD NIXDORF INC (DBD)
US2536512021 - Common Stock
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 32 industry peers in the Technology Hardware, Storage & Peripherals industry. While DBD is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on DBD.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
DBD had a positive operating cash flow in the past year.
DBD had negative earnings in 4 of the past 5 years.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DBD (56.23%) is better than 100.00% of its industry peers.
With an excellent Return On Equity value of 217.18%, DBD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DBD has a better Return On Invested Capital (8.19%) than 68.75% of its industry peers.
DBD had an Average Return On Invested Capital over the past 3 years of 4.34%. This is significantly below the industry average of 17.07%.
The last Return On Invested Capital (8.19%) for DBD is above the 3 year average (4.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 56.23% | ||
| ROE | 217.18% | ||
| ROIC | 8.19% |
ROA(3y)3.95%
ROA(5y)-0.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)4.34%
ROIC(5y)4.03%
1.3 Margins
With an excellent Profit Margin value of 56.73%, DBD belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
DBD has a Operating Margin of 6.81%. This is in the better half of the industry: DBD outperforms 68.75% of its industry peers.
In the last couple of years the Operating Margin of DBD has grown nicely.
The Gross Margin of DBD (23.76%) is worse than 65.63% of its industry peers.
DBD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.81% | ||
| PM (TTM) | 56.73% | ||
| GM | 23.76% |
OM growth 3Y7.99%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.9%
GM growth 5Y3.02%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DBD is destroying value.
Compared to 1 year ago, DBD has less shares outstanding
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
DBD has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.73, we must say that DBD is in the distress zone and has some risk of bankruptcy.
DBD has a Altman-Z score of 1.73. This is comparable to the rest of the industry: DBD outperforms 53.13% of its industry peers.
DBD has a debt to FCF ratio of 40.45. This is a negative value and a sign of low solvency as DBD would need 40.45 years to pay back of all of its debts.
DBD has a Debt to FCF ratio (40.45) which is in line with its industry peers.
DBD has a Debt/Equity ratio of 1.10. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of DBD (1.10) is worse than 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.1 | ||
| Debt/FCF | 40.45 | ||
| Altman-Z | 1.73 |
ROIC/WACC0.84
WACC9.71%
2.3 Liquidity
A Current Ratio of 1.42 indicates that DBD should not have too much problems paying its short term obligations.
DBD has a worse Current ratio (1.42) than 65.63% of its industry peers.
DBD has a Quick Ratio of 1.42. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.95, DBD is doing worse than 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
DBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3025.00%, which is quite impressive.
Looking at the last year, DBD shows a small growth in Revenue. The Revenue has grown by 7.19% in the last year.
DBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.86% yearly.
EPS 1Y (TTM)3025%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.31%
Revenue 1Y (TTM)7.19%
Revenue growth 3Y-1.23%
Revenue growth 5Y-3.86%
Sales Q2Q%1.9%
3.2 Future
The Earnings Per Share is expected to grow by 296.15% on average over the next years. This is a very strong growth
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.94% yearly.
EPS Next Y1344.18%
EPS Next 2Y296.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.37%
Revenue Next 2Y0.94%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
DBD is valuated rather expensively with a Price/Earnings ratio of 17.19.
DBD's Price/Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 68.75% of the companies in the same industry.
When comparing the Price/Earnings ratio of DBD to the average of the S&P500 Index (30.52), we can say DBD is valued slightly cheaper.
With a Price/Forward Earnings ratio of 7.30, the valuation of DBD can be described as very cheap.
Based on the Price/Forward Earnings ratio, DBD is valued cheaper than 93.75% of the companies in the same industry.
DBD is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.19 | ||
| Fwd PE | 7.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 96.88% of the companies listed in the same industry.
DBD's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.35 | ||
| EV/EBITDA | 5.96 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DBD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as DBD's earnings are expected to grow with 296.15% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y296.15%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DIEBOLD NIXDORF INC
NYSE:DBD (9/13/2024, 8:08:42 PM)
After market: 42.97 0 (0%)42.97
+1.09 (+2.6%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.61B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.19 | ||
| Fwd PE | 7.3 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 56.23% | ||
| ROE | 217.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 6.81% | ||
| PM (TTM) | 56.73% | ||
| GM | 23.76% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.1 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3025%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y1344.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.19%
Revenue growth 3Y-1.23%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y